Author: devcuration

Kinaset Therapeutics just locked in $103M for a Series B, and this one moves air with intent. Boston DNA, Medfield address, global ambition. A clinical stage company betting that asthma treatment should stay where asthma actually lives, in the lungs, not roaming the bloodstream looking for trouble. Founded in 2020 by Robert Clarke, PhD, Roger Heerman, MBA, and Frazer Morgan, Kinaset Therapeutics feels less like a startup and more like a calculated return by people who already know how this movie usually ends. These are operators who have watched respiratory medicine plateau while patients kept coughing through “standard of care.”…

There is a quiet problem hiding inside very loud biotech breakthroughs. Therapeutics keep getting smarter, more complex, more computational. Manufacturing keeps reminding everyone that biology does not care about vision decks or valuation comps. Avenue Biosciences lives right in that friction. Founded in 2023 as a University of Helsinki spinout, operating between Palo Alto and Helsinki, the company is going straight at one of the most expensive bottlenecks in biologics: getting proteins out of the cell efficiently, repeatedly, and without touching what makes them therapeutically sacred. The science showed up first. Years of work inside the Institute of Biotechnology under…

Thirty years in healthcare is a long time to watch smart systems forget the human on the other side of the screen. Brado started in 1996 as a creative agency, then did something most firms never do. It listened longer than it talked. That instinct evolved into healthcare journey research, then digital engagement, and now conversational AI built on lived evidence, not vibes. That arc is why the strategic investment from Santé Ventures lands with weight. This is not capital chasing trend lines. It is capital recognizing depth, timing, and restraint. Santé Ventures does not manage $1B+ by betting on…

AI4Eyes Medical Technologies has been operating with the patience of people who understand that credibility in medtech is earned, not announced. Built between Montreal and Vancouver, this AI-driven medical device company is focused on ocular diagnostics, a corner of healthcare where speed, accuracy, and consistency decide outcomes long before marketing ever gets a vote. Eyecare has lived with fragmented workflows, stacked devices, and slow feedback loops for years. AI4Eyes did not try to polish that system. They condensed it until it finally made sense. In Q4 2025, AI4Eyes Medical Technologies secured $6.5M CAD through a disciplined internal financing round. $3.7M…

BlueNalu never chased volume. It chased value, patience, and physics. In an industry that treats seafood like a commodity until the ocean sends the invoice, this San Diego company aimed straight at the most unforgiving cut on the menu: bluefin tuna toro. The kind chefs guard. The kind markets ration. The kind that exposes pretenders fast. You do not touch toro unless your science, supply chain, and economics can all sit at the same table without flinching. January 2026 arrives with BlueNalu closing an $11M insider-led financing, structured across convertible notes and preferred stock, led by Agronomics, Siddhi Capital, and…

Some problems in banking scream for attention. Others just sit there, quietly dragging deals into the mud while everyone shrugs and calls it “process.” Commercial account switching has lived in that second category for decades. Not broken enough to spark revolt. Painful enough to cost real money. Onsetto exists because Cale Johnston has already seen what happens when friction gets ignored, solved, sold, and then politely forgotten by the market. Minneapolis has a habit of producing builders who do not chase volume; they chase leverage. Onsetto was founded in 2025 by Cale Johnston after scaling ClickSWITCH into an industry standard…

There is a moment in every industry when the noise drops and the signal gets loud. Healthcare is in one of those moments, and Apella just turned the volume knob with an $80M Series B that feels less like a raise and more like a declaration. Founded in 2019 and based in San Francisco, Apella is doing the unglamorous work that actually moves the needle: making operating rooms run on truth instead of gut feel. Ambient AI, computer vision, and real-time operational intelligence quietly watching the room, learning the room, and giving hospitals back the rarest asset they have, which…

Valinor Enterprises did not show up to chase headlines. It showed up to chase problems the rest of the market keeps stepping over. Founded in 2024 and built out of Washington, D.C., Valinor is an operating holding company in the original sense of the word. It holds reality. The kind operators deal with when connectivity drops, supply chains crack, and the mission still does not care. Julie Bush built this after more than a decade inside Palantir and time on Capitol Hill, alongside Paul Kwan, Trae Stephens, and Grant Verstandig, four people who know exactly where theory dies and execution…

In 2017, while most of Silicon Valley was busy optimizing clicks and dopamine loops, Blackbird.AI took a quieter, sharper flight path. Founded by Wasim Khaled and Dr. Naushad UzZaman, two computer scientists who understood the next real threat would not crash servers but crash trust, the company set out to confront narrative attacks before the term showed up in board decks. Computational propaganda, info ops, synthetic amplification. Not theory. Not vibes. Real forces already bending markets, elections, and reputations in plain sight. Blackbird.AI secured a $28M strategic investment, bringing total capital raised to $58M. The round was led by Ten…

Insurance has always been the quiet room where innovation goes to wait. Paper forms. Annual cycles. Brokers translating yesterday’s risk for tomorrow’s companies. Corgi walked into that room like a corgi puppy with a badge and a mission, tail wagging, teeth sharp, knocking over the furniture with intent. AI-native. Full-stack carrier. Built in San Francisco in 2024 for companies that move at cloud speed and think in commits, not calendar years. This is not software taped onto insurance. This is insurance built for velocity. Nicolas S. Laqua and Emily Yuan did not come up through actuarial hallways, and that is…